ASX Announcement

Results of Annual General Meeting

Sydney, Australia, 11 November 2026: Imugene Limited (ASX:IMU) (Imugene, or the Company) is pleased to announce the results of today's Annual General Meeting.

The results are set out in the attached document, in accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act 2001 (Cth).

It is noted that all resolutions put to the meeting were decided by way of a poll and were carried.

Release approved by the Company Secretary on behalf of the Board.

For more information please contact:

General Investor Enquiries
shareholderenquiries@imugene.com

Media Enquiries
communications@imugene.com

Connect with us on LinkedIn @Imugene Limited
Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)

Imugene is a clinical stage cell therapy company developing an allogeneic CAR T for blood cancers. Our lead asset is an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and together with leading specialists and medical professionals, we believe Imugene's cellular therapy may become foundation treatments for cancer. Our goal is to ensure that Imugene is at the forefront of this rapidly growing global market.

Results of Meeting

Imugene Limited

Imugene Limited - Annual General Meeting

Wednesday, 11 November 2026

Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

		Proxy Votes (as at proxy voting close)				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
1 Remuneration Report	P	70,622,743 79.22%	17,564,502 19.70%	89,262	956,146 1.07%	71,819,182 80.32%	17,597,047 19.68%	89,262	Carried
2 Re-election of Director – Ms Kim Drapkin	P	99,487,880 96.00%	3,154,928 3.04%	171,646	994,555 0.96%	97,150,557 96.59%	3,427,869 3.41%	171,646	Carried
3 Election of Director – Mr Michael Kotsanis	P	99,344,030 95.98%	3,164,290 3.06%	306,134	994,555 0.96%	97,247,000 96.82%	3,196,938 3.18%	306,134	Carried
4 Election of Director – Dr Charmaine Gittleson	P	100,339,171 96.86%	2,256,666 2.18%	218,617	994,555 0.96%	98,242,141 97.72%	2,289,314 2.28%	218,617	Carried
5 Approval of Employee Share Option Plan	P	85,581,447 92.81%	5,632,069 6.11%	352,283	995,699 1.08%	83,245,371 93.38%	5,904,907 6.62%	352,283	Carried
6 Approval of 10% capacity under Listing Rule 7.1A	P	97,769,707 94.69%	4,437,957 4.30%	557,688	1,043,657 1.01%	95,721,882 95.54%	4,470,502 4.46%	557,688	Carried
7 Ratification of prior issue of TAR Convertible Notes to CVI Investments, Inc.	P	93,027,759 94.90%	3,935,081 4.01%	5,786,755	1,059,414 1.08%	90,995,691 95.82%	3,967,626 4.18%	5,786,755	Carried
8 Ratification of prior issue of New Subscription Warrants to CVI Investments, Inc.	P	92,696,083 94.85%	3,963,226 4.06%	6,082,235	1,067,465 1.09%	90,672,066 95.78%	3,995,771 4.22%	6,082,235	Carried